Dr Reddy's Expansion Plans for API Production

Dr. Reddy’s expansion plans for API production

Unrelated to the inspection of the USFDA at the Dr. Reddys Srikakulam facility, Dr. Reddys sought permission from the Ministry of Environment, Forests & Climate Change to expand their drug and intermediate manufacturing at three locations.

All three chemical technical operation (CTO) units, CTO-I, CTO-II & CTO-III are located in Medak district and the announced planned capacity increases along with the anticipated capital investment were

	Existing Capacity	Planned Capacity	Anticipated Investment
CTO I	14.7 TPM	45.5 TPM	Rs 30 crores
CTO II	21.9 TPM	68.9 TPM	Rs 45 crores
CTO - III	4.45 TPM	28.1 TPM	Rs 12 crores

*$1 million is approximately about Rs 6.2 crores & TPM is tons per month

In addition, the declaration given by Dr. Reddys also mentions the various products which will be produced at each facility (table below).

Needless to say, the plans are ambitious however with the growth witnessed by the Indian pharmaceutical industry over the past decade, one can understand Dr. Reddys commitment to investing further in their business.

Table Dr. Reddys production plans at various facilities

Product Name	Planned Capacity (TPM)	Facility Location
Alendronate Sodium Trihydrate	6.67	CTO - III
Alfuzosin	2.33	CTO - I
Altretamine	0.03	CTO - I
Amlodipine Besylate	33.33	CTO - II
Amlodipine Besylate	133.33	CTO - III
Amlodipine Besylate ( Ethyl 4 [2- (pthalamide)ethoxy] aceto acetate (TDM-2)	100	CTO - II
Amlodipine Maleate	30	CTO - III
Amsacrine	0.07	CTO - I
Anastrazole	0.83	CTO - II
Aprepitant	3.33	CTO - III
Aripiprazole	0.33	CTO - II
Atomoxetine	1.67	CTO - III
Atorvastatin	375.83	CTO - II
Azacitidine	0.67	CTO - I
Bicalutamide	0.03	CTO - II
Bivalirudin	0.03	CTO - II
Bivalirudin Trifluoro Acetate	0.03	CTO - I
Bortezomib	0.03	CTO - I
Cabazitaxel	0.02	CTO - I
Candesartan cilexetil	6.67	CTO - II
Cetirizine Hydrochloride	66.67	CTO - I
Cetirizine	16.67	CTO - II
Ciprofloxacin	176.67	CTO - II
Ciprofloxacin HCl	533.33	CTO - II
Ciprofloxacin Lactate	33.33	CTO - II
Clopidogrel Bisulfate	500	CTO - I
Clopidogrel Premix	166.67	CTO - II
Diluted Everolimus 5% (Everolimus)	0.33	CTO - II
Disodium Pamidronate	0.33	CTO - III
Docetaxel	1.9	CTO - I
Dutasteride	3.33	CTO - II
Esomeprazole magnesium	66.67	CTO - III
Ezetimibe	3.33	CTO - II
Fexofenadine Hydrochloride	500	CTO - I
Finasteride	10	CTO - II
Fluoxetine	110	CTO - I
Fondaparinux Sodium	0.33	CTO - II
Galantamine	0.03	CTO - II
Gemcitabine	13.33	CTO - I
Glimepiride	13.33	CTO - II
Imatinib	0.17	CTO - I
Irinotecan	0.33	CTO - I
Ketorolac	66.67	CTO - II
Lacidipine	5	CTO - III
Lamotrigine	33.33	CTO - I
Lansoprozole	8.33	CTO - III
Letrozole	0.03	CTO - II
Levocetrizine Di HCl	10	CTO - III
Levofloxacin	200	CTO - II
Lomustine	1.33	CTO - I
Losartan Postassium	150	CTO - I
Meloxicam	0.03	CTO - I
Memantine HCl	3.33	CTO - II
Mesalamine	0.03	CTO - II
Metoprolol Succinate	266.67	CTO - II
Moxifloxacin	116.67	CTO - II
Norfloxacin	0.03	CTO - I
Omeprazole	133.33	CTO - III
Omeprazole Magnesium	50	CTO - III
Omeprazole Sodium	10	CTO - III
Omerprazole Form B	33.33	CTO - III
Paclitaxel	0.33	CTO - I
Pantoprazole Sodium	100	CTO - III
paroxetine HCl	0.03	CTO - II
Pemetrexed	0.67	CTO - I
Rabeprazole Sodium	83.33	CTO - III
Raloxifene	33.33	CTO - II
Ramipril	100	CTO - III
Repaglinide	6.67	CTO - II
Rivastigmine	6.67	CTO - II
Risperidone	13.33	CTO - I
Rivastigmine	6.667	CTO - I
Rizatriptan Benzoate	1.33	CTO - II
Rocuronium Bromide	0.03	CTO - II
Ropinrole HCl	1.83	CTO - III
Rosiglitazone	3.33	CTO - II
Sparfloxacin	3.33	CTO - I
Tacrolimus	5	CTO - II
Tadalafil	3.33	CTO - II
Telmisartan	100	CTO - II
Temozolamide	0.03	CTO - I
Terbinafine HCl	133.33	CTO - III
Tizanidine HCl	16.67	CTO - III
Topotecan	0.07	CTO - I
valganciclovir	0.03	CTO - I
Vardenafil	3.33	CTO - II
Voriconazole	8.33	CTO - III
Ziprasidone Hydrochloride	100	CTO - I
Zoledronic acid	0.33	CTO - III
Zolmitriptan	0.83	CTO - I
Zonisamide	0.03	CTO - II

The PharmaCompass Newsletter – Sign Up, Stay Ahead

Feedback, help us to improve. Click here

Image Credit : Sprint006 plan by Jez Nicholson is licensed under CC BY 2.0

“ The article is based on the information available in public and which the author believes to be true. The author is not disseminating any information, which the author believes or knows, is confidential or in conflict with the privacy of any person. The views expressed or information supplied through this article is mere opinion and observation of the author. The author does not intend to defame, insult or, cause loss or damage to anyone, in any manner, through this article.”

BLOG

MARKET INTEL by PharmaCompass

CONTENT by Suppliers

News